These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8920173)

  • 1. Thrombolytic therapy in the elderly. Pharmacoeconomic considerations.
    Ramanathan K; Ellis CJ; White HD
    Drugs Aging; 1996 Apr; 8(4):237-44. PubMed ID: 8920173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.
    Barradell LB; Goa KL
    Pharmacoeconomics; 1995 Nov; 8(5):428-59. PubMed ID: 10172669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.
    Gillis JC; Wagstaff AJ; Goa KL
    Drugs; 1995 Jul; 50(1):102-36. PubMed ID: 7588083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Streptokinase. A pharmacoeconomic appraisal of its use in the management of acute myocardial infarction.
    Gillis JC; Goa KL
    Pharmacoeconomics; 1996 Sep; 10(3):281-310. PubMed ID: 10163575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the French setting.
    Pelc A; Dardenne J; Frelon JH; Hanania G
    Pharmacoeconomics; 1997 Jun; 11(6):595-605. PubMed ID: 10173031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
    Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
    J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS; White HD
    Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction.
    Krumholz HM; Pasternak RC; Weinstein MC; Friesinger GC; Ridker PM; Tosteson AN; Goldman L
    N Engl J Med; 1992 Jul; 327(1):7-13. PubMed ID: 1598117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of thrombolytic treatment for myocardial infarction: comparison of anistreplase, alteplase and streptokinase in 270 patients treated within 4 hours.
    Machecourt J; Dumoulin J; Calop J; Foroni L; Terisse MP; Henon T; Vanzetto G; Denis B; Bassand JP; Cassagnes J
    Eur Heart J; 1993 Jan; 14(1):75-83. PubMed ID: 8432296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction.
    Kellett J; Clarke J
    Med Decis Making; 1995; 15(4):297-310. PubMed ID: 8544674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of thrombolytic therapy on parameters of endothelial function in patients with myocardial infarction].
    Barbarash OL; Kashtalap VV; Voroncova NL; Suslova TE; Karetnikova VN; Barbarash LS
    Kardiologiia; 2007; 47(10):54-8. PubMed ID: 18260945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Streptokinase versus alteplase in acute myocardial infarction.
    Friedman HS
    J R Soc Med; 1996 Aug; 89(8):427-30. PubMed ID: 8795494
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
    Naylor CD; Bronskill S; Goel V
    Can J Cardiol; 1993; 9(6):553-8. PubMed ID: 8221354
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost and quality of life: thrombolysis and primary angioplasty.
    Goldman L
    J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):38S-41S. PubMed ID: 7775713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
    Goel V; Naylor CD
    Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.